Compare NTRA & TDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | TDY |
|---|---|---|
| Founded | 2003 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 23.4B |
| IPO Year | 2015 | 1999 |
| Metric | NTRA | TDY |
|---|---|---|
| Price | $244.52 | $521.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | $227.69 | ★ $606.29 |
| AVG Volume (30 Days) | ★ 1.7M | 415.1K |
| Earning Date | 11-06-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.26 |
| Revenue | $2,116,676,000.00 | ★ $6,005,400,000.00 |
| Revenue This Year | $32.77 | $8.24 |
| Revenue Next Year | $16.51 | $4.73 |
| P/E Ratio | ★ N/A | $30.26 |
| Revenue Growth | ★ 38.17 | 7.38 |
| 52 Week Low | $125.38 | $419.00 |
| 52 Week High | $245.59 | $595.99 |
| Indicator | NTRA | TDY |
|---|---|---|
| Relative Strength Index (RSI) | 80.03 | 56.07 |
| Support Level | $233.67 | $491.28 |
| Resistance Level | $240.18 | $504.52 |
| Average True Range (ATR) | 7.39 | 10.31 |
| MACD | 0.68 | 4.38 |
| Stochastic Oscillator | 97.49 | 95.84 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Teledyne Technologies Inc sells technologies for industrial markets. Roughly a fourth of Teledyne's revenue comes from contracts with the United States government. The firm operates in four segments: instrumentation, digital imaging, aerospace and defense electronics, and engineered systems. The instrumentation segment provides monitoring instruments primarily for marine and environmental applications. The digital imaging segment contributes majority of proportion of revenue and includes image sensors and cameras for industrial, government, and medical customers. The aerospace and defense electronics segment provides electronic components and communication products for aircraft. The engineered systems segment provides solutions for defense, space, environmental, and energy applications.